SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Morepen Laboratories - Quaterly Results

16 May 2023 Evaluate
A slight decline in the revenue of Rs. 3365.24 millions was seen for the March 2023 quarter as against Rs. 3424.42 millions during year-ago period.A slender decline of -28.02% was recorded to Rs. 102.75  millions from Rs. 142.74 millions in the corresponding previous quarter.Operating profit for the quarter ended March 2023 decreased to 181.17 millions as compared to 222.87 millions of corresponding quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 3365.24 3424.42 -1.73 13388.83 14492.67 -7.62 13388.83 14492.67 -7.62
Other Income 29.88 31.08 -3.86 57.59 102.35 -43.73 57.59 102.35 -43.73
PBIDT 181.17 222.87 -18.71 830.29 1393.72 -40.43 830.29 1393.72 -40.43
Interest 5.62 7.96 -29.40 19.81 -73.66 -126.89 19.81 -73.66 -126.89
PBDT 175.55 214.91 -18.31 810.48 1467.38 -44.77 810.48 1467.38 -44.77
Depreciation 46.14 48.20 -4.27 180.06 211.95 -15.05 180.06 211.95 -15.05
PBT 129.41 166.71 -22.37 630.42 1255.43 -49.78 630.42 1255.43 -49.78
TAX 26.66 23.97 11.22 167.99 244.82 -31.38 167.99 244.82 -31.38
Deferred Tax 2.03 24.83 -91.82 2.03 24.83 -91.82 2.03 24.83 -91.82
PAT 102.75 142.74 -28.02 462.43 1010.61 -54.24 462.43 1010.61 -54.24
Equity 1022.27 955.59 6.98 1022.27 955.59 6.98 1022.27 955.59 6.98
PBIDTM(%) 5.38 6.51 -17.28 6.20 9.62 -35.51 6.20 9.62 -35.51

Morepen Laboratories Share Price

41.92 0.79 (1.92%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×